EP3580355A4 - S100bêta et ses isoformes pour la détection d'affections neurologiques - Google Patents
S100bêta et ses isoformes pour la détection d'affections neurologiques Download PDFInfo
- Publication number
- EP3580355A4 EP3580355A4 EP18751838.6A EP18751838A EP3580355A4 EP 3580355 A4 EP3580355 A4 EP 3580355A4 EP 18751838 A EP18751838 A EP 18751838A EP 3580355 A4 EP3580355 A4 EP 3580355A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- isoforms
- detection
- neurological conditions
- neurological
- conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455787P | 2017-02-07 | 2017-02-07 | |
| PCT/US2018/017244 WO2018148294A2 (fr) | 2017-02-07 | 2018-02-07 | S100bêta et ses isoformes pour la détection d'affections neurologiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3580355A2 EP3580355A2 (fr) | 2019-12-18 |
| EP3580355A4 true EP3580355A4 (fr) | 2020-12-16 |
Family
ID=63107818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18751838.6A Pending EP3580355A4 (fr) | 2017-02-07 | 2018-02-07 | S100bêta et ses isoformes pour la détection d'affections neurologiques |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3580355A4 (fr) |
| JP (2) | JP2020507622A (fr) |
| AU (1) | AU2018219790B2 (fr) |
| WO (1) | WO2018148294A2 (fr) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2871467A1 (fr) * | 2004-06-14 | 2005-12-16 | Genoscreen Soc Par Actions Sim | Proteine cog47 et polymorphisme du gene s100 beta |
| WO2009014342A2 (fr) * | 2007-07-20 | 2009-01-29 | Young In Frontier Co., Ltd. | Marqueurs et kit de diagnostic de la maladie d'alzheimer |
| WO2010019553A2 (fr) * | 2008-08-11 | 2010-02-18 | Banyan Biomarkers, Inc. | Procédé de détection de biomarqueurs et test d'état neurologique |
| WO2011144914A2 (fr) * | 2010-05-21 | 2011-11-24 | Universite De Geneve | Méthodes de diagnostic |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1667672A4 (fr) * | 2003-10-03 | 2010-02-10 | Ono Pharmaceutical Co | Procede de prevention et/ou de traitement de maladies neurodegeneratives |
| AU2010291933B2 (en) * | 2009-09-14 | 2016-09-08 | Banyan Biomarkers, Inc. | Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury |
| WO2014194329A1 (fr) * | 2013-05-31 | 2014-12-04 | Banyan Biomarkers, Inc. | Marqueur neuronal spécifique s100β pour dosages de biomarqueurs et dispositifs utilisés dans la détection d'une affection neurologique |
-
2018
- 2018-02-07 WO PCT/US2018/017244 patent/WO2018148294A2/fr not_active Ceased
- 2018-02-07 AU AU2018219790A patent/AU2018219790B2/en active Active
- 2018-02-07 EP EP18751838.6A patent/EP3580355A4/fr active Pending
- 2018-02-07 JP JP2019563344A patent/JP2020507622A/ja active Pending
-
2022
- 2022-10-24 JP JP2022169855A patent/JP7597770B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2871467A1 (fr) * | 2004-06-14 | 2005-12-16 | Genoscreen Soc Par Actions Sim | Proteine cog47 et polymorphisme du gene s100 beta |
| WO2009014342A2 (fr) * | 2007-07-20 | 2009-01-29 | Young In Frontier Co., Ltd. | Marqueurs et kit de diagnostic de la maladie d'alzheimer |
| WO2010019553A2 (fr) * | 2008-08-11 | 2010-02-18 | Banyan Biomarkers, Inc. | Procédé de détection de biomarqueurs et test d'état neurologique |
| WO2011144914A2 (fr) * | 2010-05-21 | 2011-11-24 | Universite De Geneve | Méthodes de diagnostic |
Non-Patent Citations (4)
| Title |
|---|
| BARATEIRO ANDREIA ET AL: "S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis", MOLECULAR NEUROBIOLOGY, HUMANA PRESS, US, vol. 53, no. 6, 17 July 2015 (2015-07-17), pages 3976 - 3991, XP036249031, ISSN: 0893-7648, [retrieved on 20150717], DOI: 10.1007/S12035-015-9336-6 * |
| DATABASE Geneseq [online] 23 February 2006 (2006-02-23), "Human Cog47 protein SEQ ID NO:1.", XP055747735, retrieved from EBI accession no. GSP:AEE63197 Database accession no. AEE63197 * |
| GONCALVES C A ET AL: "Biological and methodological features of the measurement of S100B, a putative marker of brain injury", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 41, no. 10-11, 1 July 2008 (2008-07-01), pages 755 - 763, XP022732684, ISSN: 0009-9120, [retrieved on 20080418], DOI: 10.1016/J.CLINBIOCHEM.2008.04.003 * |
| HEIZMANN C W ET AL: "S100 proteins: structure, functions and pathology", FRONTIERS IN BIOSCIENCE, FRONTIERS IN BIOSCIENCE, ALBERTSON, NY, US, vol. 7, 1 May 2002 (2002-05-01), pages d1356 - d1368, XP002394878, ISSN: 1093-9946 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023017805A (ja) | 2023-02-07 |
| JP2020507622A (ja) | 2020-03-12 |
| CA3052636A1 (fr) | 2018-08-16 |
| JP7597770B2 (ja) | 2024-12-10 |
| AU2018219790A1 (en) | 2019-08-22 |
| AU2018219790B2 (en) | 2024-10-10 |
| WO2018148294A2 (fr) | 2018-08-16 |
| EP3580355A2 (fr) | 2019-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202104501UA (en) | Systems and methods for the treatment of eye conditions | |
| EP3247708A4 (fr) | Composés et procédés pour la dégradation ciblée du récepteur des androgènes | |
| EP3270917A4 (fr) | Composés et procédés de dégradation accrue de protéines ciblées | |
| EP3194014A4 (fr) | Casque pour la neurostimulation et la détection de paramètres corporels | |
| EP3212137A4 (fr) | Systèmes et procédés pour le traitement d'affections oculaires | |
| EP3723762A4 (fr) | Inhibiteurs de la voie de réponse intégrée au stress | |
| EP4022066A4 (fr) | Procédés et systèmes d'évaluation du risque de troubles d'utilisation d'une substance | |
| EP3638808A4 (fr) | Détection de régions de séquence ciblées | |
| PT3297628T (pt) | Azasetron para uso no tratamento de perda auditiva | |
| EP3429584A4 (fr) | Compositions et méthodes de traitement de la presbytie | |
| EP3310783A4 (fr) | Procédés et compositions de prévention et de traitement de la perte d'audition | |
| EP3319564B8 (fr) | Dispositif de grattoir ophtalmique et procédé de fabrication de celui-ci | |
| EP3684383A4 (fr) | Méthodes et systèmes destinés à la détection de troubles tissulaires | |
| EP3371154A4 (fr) | Dérivés hétérocycliques et leur utilisation pour le traitement de troubles du snc | |
| EP3580355A4 (fr) | S100bêta et ses isoformes pour la détection d'affections neurologiques | |
| EP3298159A4 (fr) | Procédés pour augmenter l'extraction d'enzymes d'aliment pour animaux et pour mesurer leur activité | |
| HK40071463B (en) | Antisense oligomers for treatment of conditions and diseases | |
| HK40064034B (en) | Antisense oligomers for treatment of conditions and diseases | |
| EP3256144A4 (fr) | Inhibition peptidique des maladies ou affections médiées par le ccr3 | |
| HK40031149A (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| HK40032684A (en) | Antisense oligomers for treatment of conditions and diseases | |
| HK40033359A (en) | Interleukin-18 variants and methods of use | |
| HK40012950A (en) | Methods and processes for assessment of genetic variations | |
| AU2018902206A0 (en) | Methods and systems for assessing the risk of glaucoma | |
| AU2017905098A0 (en) | Method of treating or preventing neurological diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20190906 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20201118 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12Q 1/6883 20180101ALI20201112BHEP Ipc: C07K 16/18 20060101ALI20201112BHEP Ipc: C12Q 1/68 20180101AFI20201112BHEP Ipc: G01N 33/68 20060101ALI20201112BHEP Ipc: G01N 33/564 20060101ALI20201112BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20231124 |